Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.

Organic anion transporting polypeptide 1B3 (OATP1B3, SLCO1B3) is normally expressed in hepatocytes. In this study, we showed frequent overexpression of OATP1B3 in colorectal adenocarcinomas. Quantitative reverse transcription-PCR analysis of 17 colon tumors indicated tumoral overexpression of OATP1B3 by approximately 100-fold, compared with 20 normal colon samples (P < 0.0001). Using immunohistochemistry on a tissue microarray containing 93 evaluable colon tumor specimens, we detected immunostaining of OATP1B3 in 75 colon adenocarcinomas (81%) and no immunostaining in normal samples. To determine the functional effects of OATP1B3 expression on drug-induced apoptosis, we used camptothecin and oxaliplatin on a panel of colorectal cancer cell lines stably overexpressing OATP1B3. The results indicated that OATP1B3 overexpression enhanced cell survival in RKO, HCT-8, and HCT116(p53+/+) cells that harbor wild-type p53 but not in Caco-2 and HCT116(p53-/-) cells that lack p53, compared with the respective empty vector controls (P < 0.01). The terminal deoxynucleotidyl transferase-mediated nick-end labeling assay confirmed that HCT116(p53+/+) cells overexpressing OATP1B3 had significantly lower apoptotic levels compared with empty vector control (P < 0.001). The overexpression of OATP1B3 reduced the transcriptional activity of p53, with subsequent reductions in transcript and protein levels of its downstream transcription targets (P21WAF1 and PUMA). Overexpression of a point mutation (G583E) variant of OATP1B3 lacking transport activity did not confer an antiapoptotic effect or affect p53 transcriptional activity, suggesting that the antiapoptotic effect of OATP1B3 may be associated with its transport activity. Taken together, our results suggest that OATP1B3 overexpression in colorectal cancer cells may provide a survival advantage by altering p53-dependent pathways.

[1]  T. Abe,et al.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. , 2001, Gastroenterology.

[2]  J. Reynolds,et al.  P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.

[3]  A. Watson.  An overview of apoptosis and the prevention of colorectal cancer. , 2006, Critical reviews in oncology/hematology.

[4]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[5]  R. Kim,et al.  Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.

[6]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Johnstone,et al.  P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. , 1999, Blood.

[8]  M. Gottesman,et al.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.

[9]  Jian Yu,et al.  The transcriptional targets of p53 in apoptosis control. , 2005, Biochemical and biophysical research communications.

[10]  D. Kerr,et al.  The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[12]  J. Robert,et al.  Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. , 2006, Biochemical pharmacology.

[13]  W. El-Rifai,et al.  p73 Isoforms Can Induce T-Cell Factor–Dependent Transcription in Gastrointestinal Cells , 2004, Cancer Research.

[14]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[15]  D. Kerr,et al.  Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Johnston,et al.  Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.

[17]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Keppler,et al.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[19]  T. Rikiyama,et al.  Human liver‐specific organic anion transporter‐2 is a potent prognostic factor for human breast carcinoma , 2007, Cancer science.

[20]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[21]  I. Tamai,et al.  Suppression of Cell Proliferation by Inhibition of Estrone-3-Sulfate Transporter in Estrogen-Dependent Breast Cancer Cells , 2005, Pharmaceutical Research.

[22]  C. Sassoli,et al.  P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. , 2006, Experimental cell research.

[23]  P. Hall,et al.  Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.

[24]  Jesse D. Martinez,et al.  Deoxycholic Acid Induces Intracellular Signaling through Membrane Perturbations* , 2006, Journal of Biological Chemistry.

[25]  J. González‐Gallego,et al.  Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. , 2003, The Biochemical journal.

[26]  R. Goldberg,et al.  Colorectal cancer. , 2007, Mayo Clinic proceedings.

[27]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[28]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[29]  D. Keppler,et al.  ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. , 2005, Cancer research.

[30]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[31]  T. Abe,et al.  Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3 Published, JLR Papers in Press, March 13, 2006. , 2006, Journal of Lipid Research.

[32]  Martin F. Fromm,et al.  The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3 , 2007, Drug Metabolism and Disposition.

[33]  J. Cidlowski,et al.  SLCO/OATP-like Transport of Glutathione in FasL-induced Apoptosis , 2006, Journal of Biological Chemistry.

[34]  T. Abe,et al.  Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. , 2008, Cancer letters.

[35]  I. Tamai,et al.  Involvement of Estrone-3-Sulfate Transporters in Proliferation of Hormone-Dependent Breast Cancer Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[36]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[37]  R. Houlston,et al.  A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  W. Bodmer,et al.  Genetic pathways in colorectal and other cancers. , 1999, European journal of cancer.

[39]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[40]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[42]  Hui-ying Yu,et al.  Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells , 2007, Molecular Cancer Therapeutics.

[43]  Sissy M Jhiang,et al.  PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer , 2007, BMC Cancer.

[44]  T. Wang,et al.  The gastrin gene promoter is regulated by p73 isoforms in tumor cells , 2006, Oncogene.

[45]  W. Jiang,et al.  The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. , 2006, Anticancer research.

[46]  Sakari Knuutila,et al.  Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. , 2005, Cancer research.

[47]  G. Poirier,et al.  Poly(ADP-ribosylation) and apoptosis , 2004, Molecular and Cellular Biochemistry.

[48]  B. Blumberg,et al.  Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. , 2006, Cancer research.

[49]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[50]  S. Markowitz,et al.  Genetic and epigenetic alterations in colon cancer. , 2002, Annual review of genomics and human genetics.

[51]  Ying Liu,et al.  Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Jian Yu,et al.  No PUMA, no death: implications for p53-dependent apoptosis. , 2003, Cancer cell.

[53]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.